

DAFTAR PUSTAKA

1. Dugar S, Choudary C, Duggal A. Sepsis and septic shock: Guideline based management. *cleveland clinic journal of medicine* 2020; 82 (1):53-64
2. Kristina E, Sarah C, Kareha M, Katya A, Derrick T, Daniel R, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *Lancet* 2020; 395: 200–11
3. Blanco J, Muriel-Bombin A, Sagredo V. Incidence, organ dysfunction and mortality in severe sepsis: a spanish multicentre study. *Critical Care (London, England)*. 2008; 12: R158
4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Atlanta, GA: CDC; 2019.
5. Breijyeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. *Molecules* 2020; 25: 1340
6. Parmanik A, Das S, Kar B, Bose A, Dwivedi GR, Pandey MN. Current treatment strategies against multidrug-resistant bacteria: a review. *Current Microbiology* 2022; 79:388
7. WHO. Global antimicrobial resistance and use surveillance system (GLASS) report. WHO.2021
8. Shaikh S, Fatima J, Shakil S. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi Journal of Biological Sciences*, 2015; 22: 90–101

9. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant enterobacteriaceae: epidemiology and prevention. *Clinical Infectious Diseases* 2011;53(1):60–67
10. Sharon JP, Gavin KP. Mechanisms of MRSA resistance. *Annual Review of Biochemistry* 2015.
11. Ahmed MO, Baptiste KE. Vancomycin-resistant enterococci: a review of antimicrobial resistance mechanisms and perspectives of human and animal health. *microbial drug resistance* 2017; 24(5): 590-606
12. Fadrian, Linosefa. Buku saku antibiogram RSUP Dr. M. Djamil Padang tahun 2021. Komite Pengendalian Resistensi Antibiotik. 2021
13. Murray J, Bacci S, Hogberg LD, Kaczmarek M, Keramarou M, Lamb F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022; 399: 629–55
14. Barassa-Villar JI, Aibar-Remon C, Prieto-Andres P. Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms. *Clinical Infectious Diseases* 2017; 00(00): 644–652
15. Cindy WS. Emergence of extended-spectrum beta-lactamases in our community – what does it mean for clinicians. *the hong kong medical diary*, 2011; 16(4): 23-25
16. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales

- (CRE), and *Pseudomonas aeruginosa* with Difficult-to-Treat Resistance (DTR- *P.aeruginosa*). *Clin Infect Dis* 2022; 75: 187–212
17. Pruinelli L, Westra BL, Yadav P, Hoff A, Steinbach M, Kumar V, et al. Delay within the 3-hour surviving sepsis campaign guideline on mortality for patients with severe sepsis and septic shock. *Crit Care Med*. 2018; 46:500– 505
 18. Evans L, Rhodes A, Alhazzani W, Antonelli M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med* (2021) 47:1181–1247
 19. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Gillamant C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. *Critical Care* 2014, 18:596
 20. Martin-Loeches I, Guia MC, Vallecoccia MS, Suarez D, Ibarz M, Irazabal M, et al. Risk factors for mortality in elderly and very elderly critically ill patients with sepsis: a prospective, observational, multicenter cohort study. *Ann. Intensive Care* 2019; 9:26
 21. Raith EP, Udy AA, Bailey M, McGloughlin S, McIsaac C, Bellomo R, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. *JAMA*. 2017;317(3):290-300
 22. Liu Z, Meng Z, Li Y, Zhao J, Wu S, Gou S, et al. Prognostic accuracy of the serum lactate level, the SOFA score and the qSOFA score for

- mortality among adults with Sepsis. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine* 2019; 27:51
23. Mervyn S, Clifford S, Christopher W, Manu S, Djillali A, Michael B, et al. The third international consensus definitions for sepsis and septic shock (Sepsis3). *JAMA* 2016; 315(8): 801–810
 24. Niederman MS, Baron RM, Bouadma L, Calandra T. Initial antimicrobial management of sepsis. *Crit Care Med.* 2021 25:307.
 25. Keputusan Menteri Kesehatan Republik Indonesia. Pedoman nasional pelayanan kedokteran tata laksana sepsis, 2017. 29.
 26. Hidayati, Arifin H, Raveinal. Kajian penggunaan antibiotik pada pasien sepsis dengan gangguan ginjal. *Jurnal Sains Farmasi dan Klinis* 2016; 2(2): 129-137
 27. Suwondo VN, Jatmiko HD, Hendrianingtyas M. Karakteristik dasar pasien sepsis yang meninggal di ICU RSUP dr.Kariadi Semarang periode 1 januari – 31 desember 2014. *Media Medika Muda* 2015; 4(4): 1586-1596
 28. Min H, Shaoli C, Jingqian S. The pathogenesis of sepsis and potential therapeutic targets. *Int. J. Mol. Sci.* 2019, 20: 5376
 29. Bishal G, Karan R, Amit S. Sepsis: The evolution in definition, pathophysiology, and management. *SAGE Open Medicine* 2019; Volume 7: 1– 13
 30. Seymour CW, Angus DC. Sepsis and septic shock. In J. L. Jameson, A. S. Fauci, D. L. Kasper, S. L. Hauser, D. L. Longo, & J. Loscalzo (Eds.), *Harrison's principles of internal medicine* (20th ed), 2018

31. Iba T, Watanabe E, Umemura Y, Wada T, Hayashida K, Kushimoto S, et al. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. *Journal of Intensive Care* 2019; 7:32
32. Dhingra S, Rahman NA, Peile E, Rahman M, Sartelli M, Hassali MA, et al. Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter. *Frontiers in Public Health* 2020
33. Bradford PA. Extended-spectrum b-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *ClinMicrobiol Rev* 2001; 14: 933–51.
34. Wen H, Xie S, Liang Y, Liu Y, Wei H, Sun Q, et al. Direct identification, antimicrobial susceptibility testing, and extended-spectrum β -lactamase and carbapenemase detection in gram-negative bacteria isolated from blood cultures. *Infection and Drug Resistance* 2022;15 1587–1599
35. Maged M, Myrto EF, Marios D, Michail A, Eleftherios M. Comparison between carbapenems and β -lactam/ β -lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum β -lactamase-producing enterobacteriaceae: a systematic review and meta-analysis. *Open Forum Infectious Diseases*, 2017.
36. Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- β -lactamase-producing Enterobacteriaceae. *J Antimicrob Chemother* 2016; 72: 906–1

37. Aslam B, Rasool M, Muzammil S, Baker Siddique A, Nawaz Z, Shafique M et al. Carbapenem resistance: mechanisms and drivers of global menace. In: Kirmusaoğlu S, Bhonchal Bhardwaj S (eds). Pathogenic Bacteria. IntechOpen, 2020.
38. Eichenberger EM, Thaden JT. Epidemiology and mechanisms of resistance of extensively drug resistant gram-negative bacteria. *Antibiotics* 2019; 8(2): 37
39. Aurilio C, Sansone P, Barbarisi M, Pota V, Giaccari LG, Coppolino F et al. Mechanisms of Action of Carbapenem Resistance. *Antibiotics* 2022; 11: 421.
40. Lima EM, Cid PA, Beck DS, Pinheiro LHZ, Tonhá JPS, Alves MZO et al. Predictive factors for sepsis by carbapenem resistant Gram-negative bacilli in adult critical patients in Rio de Janeiro: a case-case-control design in a prospective cohort study. *Antimicrob Resist Infect Control* 2020; 9: 132
41. Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA et al. Carbapenemase-Producing Organisms: A Global Scourge. *Clin Infect Dis* 2018; 66: 1290–1297
42. Pincus D. Microbial identification using the biomérieux vitek ® 2 system. *encycl rapid microbiol methods* 2014; 2
43. Peacock SJ, Paterson GK. Mechanisms of Methicillin Resistance in *Staphylococcus aureus*. *Annu Rev Biochem* 2015; 84:577–601
44. Lade H, Kim JS. Bacterial targets of antibiotics in methicillin-resistant *staphylococcus aureus*. *Antibiotics* 2021; 10(4): 398

45. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant staphylococcus aureus in patient presenting to the hospital with pneumonia. *BMC Infectious Disease*. 2013;13(268):1-7
46. Syahniar R, Rahyana, Kharisma DS, Khatami M, Duarsa DB. Methicillinresistant Staphylococcus Aureus among clinical isolates in indonesia: a systematic review. *Biomed & Pharmajol J*. 2020;13(4):1871-8
47. Prihatini, Aryati, Hetty. Identifikasi cepat mikroorganisme menggunakan alat vitek-2. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 2007;13(3):129-32
48. Carr AL, Daley MJ, Merkel KG, Rose D. Clinical utility of methicillin-resistant staphylococcus aureus (mrsa) nasal screening for antimicrobial stewardship/ a review of current literature. *Pharmacotherapy*. 2018;38(12):1216-28.
49. Rybek MJ, Le J, Lodise TP, Levine DP, Brandley JS, Liu C. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by the american society of health-system pharmacists, the infectious diseases society of america, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. *Am J Health-Syst Pharm*. 2020;77(11):835-63
50. Chalmers SJ, Wylam MR. Methicillin-resistant staphylococcus aureus infection and treatment options. In: Ji Y, editor. *Methicillin-resistant*

staphylococcus aureus (mrsa) protocols: cutting-edge technologies and advancements third edition. New York: Humana Press. 2020; 229-52.

51. Lambert M. IDSA guidelines on the treatment of MRSA infections in adults and children. *American Family Physician*. 2011;84(4):5.
52. Halim SV, Setiawan E. Seftarolin, antibiotik baru dengan aktivitas anti-mrsa: sebuah kajian efektivitas, keamanan, dan biaya penggunaan. *Jurnal Farmasi Galenika: Galenika Journal of Pharmacy*. 2020;6(1):160-80
53. Miller WR, Murray BE, Rice LB, Arias CA. Resistance in vancomycin resistant enterococci. *Infect Dis Clin N Am*. 2020;751-771
54. Beale JW, Diioia MD. Clinical considerations in the approach to vancomycin resistant enterococci: a narrative review. *Int J Med Stud*. 2022;10(2):202-9
55. Ahmed MO, Baptiste KE. Vancomycin-resistant enterococci: a review of antimicrobial resistance mechanisms and perspectives of human and animal health. *Microbial Drug Resistance*. 2017;1-17
56. Sennang N. Masalah ketahanan (resistensi) vancomycin terhadap enterococci. *Ind J Clin Pat Med Lab*. 2008;15(1):27-33
57. Li Z, Lou Q, Xiao S, Lin Z, Liu Y, Han M, et al. Evaluation of genexpert vana/vanb in the early diagnosis of vancomycin-resistant enterococci infection. *Plos Negl Trop Dis*. 2020;15(11):1-12
58. Sy CL, Chen P, Cheng CW, Huang LJ, Wang CH, Chang TH. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. *Journal of Microbiology, Immunology and Infection*. 2022;55:359-86

59. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichly RM, Kollef MH. Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. *Crit Care Med* 2011;39(1): 46-52
60. De Pablo R, Monserrat J, Reyes E, Diaz-Martin D, Rodriguez Zapata M, Carballo F, et al. Mortality in Patients With Septic Shock Correlates With Anti-Inflammatory But not proinflammatory Immunomodulatory Molecules. *Journal of Intensive Care Medicine*, 2011; 26(2): 125–132
61. Annane D. The role of ACTH and corticosteroids for sepsis and septic shock. *front endocrinol*. 2016; 7:70
62. Dumas G, Jean-Remi L, Joffre J, Bige N, Edmilson B, Jean-Luc B, et al. Mottling score is a strong predictor of 14-day mortality in septic patients whatever vasopressor doses and other tissue perfusion parameters. *Critical Care*, 2019; 23:211.
63. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem therapy is associated with improved survival compared with piperacillin tazobactam for patients with extended spectrum β -lactamase bacteremia. *CID* 2015; 60 (5): 1319-1325
64. Wang R, Cosgrove SE, Tschudin-Sutter S, Han JH, Turnbull AE, Hsu AJ, et al. Cefepime therapy for cefepime-susceptible extended-spectrum β -lactamase-producing .enterobacteriaceae bacteremia. *OFID*, 2016.
65. Martin-Loeches I, Guia MC, Vallecoccia MS, Suarez D, Ibarz M, Irazabal M, et al. Risk factors for mortality in elderly and very elderly critically ill patients with sepsis: a prospective, observational, multicenter cohort study. *Ann. Intensive Care* 2019; 9:26

66. Blot S, Cankurtaran M, Petrovic M, Vandijck D, Lizy C, Decruyenaere J, et al. Epidemiology and outcome of nosocomial bloodstream infection in elderly critically ill patients: a comparison between middle-aged, old, and very old patients. *Crit Care Med*. 2009;37(5):1634–41
67. Ibarz M, Haas LEM, Ceccato A, Artigas A. The critically ill older patient with sepsis: a narrative review. *Annals of Intensive Care*, 2024; 14:6
68. Laksmi PW, Harimurti K, Setiati S, Soejono CH, Aries W, Roosheroe AG. Management of immobilization and its complication for elderly. *Acta Med Indones J Intern Med*, 2008;40(4): 233-240
69. Theresa A, June M. Sepsis in older adults. *Infect Dis Clin*, 2017;31:731–742
70. Sakr Y, Elia C, Mascia L, Barberis B, Cardellino S, Livigni S, et al. The influence of gender on the epidemiology of and outcome from severe sepsis. *Crit Care*. 2013;17(2):R50
71. Adrie C, Francais A, Alvarez-Gonzalez A, Mounier R, Azoulay R, Zahar J, et al. Model for predicting short-term mortality of severe sepsis. *Critical Care*. 2009; 13:R72
72. Nasir N, Jamil B, Siddiqui S, Talat N, Khan FA, Hussain R. Mortality in sepsis and its relationship with gender. *Pak J Med Sci*. 2015;31(5):1201-1206
73. Lakbar I, Einav S, Lalevee N, Martin-Loeches I, Pastene B, Leone M. Interactions between gender and sepsis implications for the future. *Microorganisms*, 2023; 11: 746

74. Tran QK. Reciprocity between estrogen biology and calcium signaling in the cardiovascular system. *Front Endocrinol*, 2020;11:568203
75. Oh Y, Roh J, Lee J, Chung HS, Lee K, Lee MK. Sequential organ failure assessment score as a predictor of mortality in ventilated patients with multidrug-resistant bacteremia. *Acute and Critical Care*. 2020; 35(3):169-178
76. Oliveira-Maia M, Gomes CD, Gomes M, Fernandes SE, Bezerra R, Queiroz D, et al. Multidrug-resistant bacteria on critically ill patients with sepsis at hospital admission: risk factors and effects on hospital mortality. *Infection and drug resistance*. 2023; 16: 1693–1704
77. Raia L, Zafrani L. Endothelial activation and microcirculatory disorders in sepsis. *Front Med*, 2022; 9:907992
78. Fadrian F, Linosefa L, Ridhwan M, Hasnah H, Ayuni AS. Multidrug-resistant organisms and determinant factors in sepsis patients. *Iran J Med Microbiol*. 2023; 17(5): 596-605
79. Al-Sunaidar KA, Aziz NA, Hassan Y, Jamshed S, Sekar M. Association of multidrug resistance bacteria and clinical outcomes of adult patients with sepsis in the intensive care unit. *Trop Med Infect Dis*. 2022; 7: 365
80. Jiang L, Cheng M. Impact of diabetes mellitus on outcomes of patients with sepsis: an updated systematic review and meta-analysis. *Diabetol Metab Syndr*. 2022; 14: 39
81. Fields LB. Oral care intervention to reduce incidence of ventilator-associated pneumonia in the neurologic intensive care unit. 2008; 40(5): 291–298

82. Gudiol C, Albasanz-Puig A, Cuervo G, Carratala J. Understanding and managing sepsis in patients with cancer in the era of antimicrobial resistance. *Front Med (Lausanne)*. 2021; 8: 636547
83. Lueangarun S, Leelarasamee A. Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: a retrospective study. *Interdisciplinary Perspectives on Infectious Diseases*. 2012; 12: 56-62
84. Wang M, Jiang L, Zhu B, Li W, Du B, Kang Y, et al. The prevalence, risk factors, and outcomes of sepsis in critically ill patients in china: a multicenter prospective cohort study. *Front Med* 2020; 7:593808
85. Pradipta IS, Sodik DC, Lestari K, Parwati I, Halimah E, Diantini A, et al. Antibiotic resistance in sepsis patients: evaluation and recommendation of antibiotic use. *North American Journal of Medical Sciences* 2013; 5(6): 344-352
86. Machado E, Costa P, Carvalho A. Occurrence of healthcare-associated infections (HAIS) by *escherichia coli* and *klebsiella* spp. producing extended-spectrum β -lactamases (ESBL) and/or carbapenemases in portuguese long-term care facilities. *Pathogens* 2022; 11: 1019
87. Iovleva A, Doi Y. Carbapenem-resistant enterobacteriaceae. *Clin Lab Med* 2017; 37: 303–315
88. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram negative bacteria. *Clin Microbiol Rev* 2012;25(3):450-70

89. Kim HJ, Oh DK, Lim SY, Cho YJ, Park S, Suh GY, et al. Antibigram of multidrug-resistant bacteria based on sepsis onset location in Korea: a multicenter cohort study. *J Korean Med Sci.* 2023; 38(10):e75
90. Ospina-Tascón GA, Hernandez G, Alvarez I, Calderon-Tapia L, Manzano-Nunez R, Sanchez-Ortiz A, et al. Effects of very early start of norepinephrine in patients with septic shock: a propensity score-based analysis. *Crit Care.* 2020;24(1):52
91. Elbouhy MA, Soliman M, Gaber A, Taema KM, Abdel-Aziz A. Early use of norepinephrine improves survival in septic shock: earlier than early. *Archives of Medical Research,* 2019; 50(6), 325–332
92. Brand DA, Patrick PA, Berger JT, Ibrahim M, Matela A, Upadhyay S, et al. Intensity of vasopressor therapy for septic shock and the risk of in-hospital death. *Journal of Pain and Symptom Management,* 2017;53(5), 938–943
93. Al-Husinat L, Alsabbah A, Hmaid AA, Athamneh R, Adwan M, Hourani MN, et al. Norepinephrine may exacerbate septic acute kidney injury: a narrative review. *J Clin Med.* 2023; 12(4): 1373
94. Sanchez C, Pinsky MR, Sinha S, Mishra RC, Lopa AJ, Chatterjee R. Fluids and early vasopressors in the management of septic shock: do we have the right answers yet? *The Journal of Critical Care Medicine* 2023;9(3):138-147
95. Constantini E, Carlin M, Porta M, Brizzi MF. Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence. *Acta Diabetol,* 2021; 58:1139–1151

96. Bonnet M, Lagier JC, Raoult D, Khelaifia S. Bacterial culture through selective and non-selective conditions: the evolution of culture media in clinical microbiology. *New microbe and new infect*, 2020; 34: 100622
97. Speiser JR, Karvellas CJ, Shumilak G, Sligl WI, Mirzanejad Y, Gurka D, et al. Predicting in-hospital mortality in pneumonia-associated septic shock patients using a classification and regression tree: a nested cohort study. *Journal of Int Care* ,2018; 6:66
98. Caraballo C, Jaimes F. Organ dysfunction in sepsis: an ominous trajectory from infection to death. *Yale journal of biology and medicine*, 2019;92: pp.629-640.
99. Rivers E, Nguyen B, Havstad S. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *New england journal medicine*, 2001; 345(19):1368–1377
100. Shapiro I, Douglas IS, Brower RG, Brown SM, Exline MC, Ginde AA, et al. Early restrictive or liberal fluid management for sepsis-induced hypotension. *N Engl J Med* 2023;388:499-510
101. Luo B, Yu Z, Li Y. Thyroid hormone disorders and sepsis. *Biomed Mater Eng*. 2017;28:S237-S241
102. Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, et al. Benefit of Appropriate Empirical Antibiotic Treatment: Thirty-day Mortality and Duration of Hospital Stay. *American Journal of Medicine*, 2006; 119: 970-976

103. Van den Bosch CM, Hulscher ME, Akkermans EP, Wille J, Geerlings SE, Prins JM. Appropriate antibiotic use reduces length of hospital stay. *Antimicrob Chemother* 2017; 72: 923–932.
104. Martínez ML, Plata-Menchaca EP, Ruiz-Rodríguez JC, Ferrer R. An approach to antibiotic treatment in patients with sepsis. *J Thorac Dis.* 2020;12(3):1007-1021.
105. Fadrian F, Ahmad A, Khairat K, Putri VY. The diagnostic value of the italian score for predicting extended-spectrum β lactamase-producing *enterobacterales* infection in sepsis patients at Dr. M. Djamil Central General Hospital Padang, Indonesia. *Biomedical and Biotechnology Research Journal*, 2024;8:ps28
106. Yungyuen T, Chatsuwat T, Plongla R, Kanthawong S, Yordpratum U, Voravuthikunchai SP, et al. Nationwide surveillance and molecular characterization of critically drug-resistant gram-negative bacteria: results of the research university network Thailand study. *Antimicrob Agents Chemother.* 2021;65(9):e00675-21
107. Fadrian F, Aliska G, Utami WN. The relationship between appropriateness of antibiotic use based on the gysens algorithm and mortality: a retrospective cohort study in Indonesian tertiary hospital. *Acta Med Indones,*

2024;56(2):137-144

